CHAMPIONS ONCOLOGY, INC.

Champions Oncology, Inc. (Nasdaq Capital Market: CSBR) operates as a technology-enabled research organization focused on creating computational and experimental solutions for drug discovery and development. The company's website is www.championsoncology.com.

The company's core business centers on three primary revenue streams. The Translational Oncology Solutions division provides research services to pharmaceutical and biotechnology companies, utilizing proprietary platforms to predict drug efficacy and identify patient populations sensitive to specific therapies. This segment generated the majority of revenues and has grown at an average annual rate of twelve percent since 2019, with typical studies priced around $125,000 and increasingly at $250,000 to $500,000 for regulatory studies. The company also offers data licensing agreements providing access to patient-derived xenograft model data through multi-omic datasets. The Software as a Service business delivers Lumin Bioinformatics, a proprietary software platform combining the company's datacenter with artificial intelligence and analytics for computational cancer research sold on annual subscription basis.

The nascent Drug Discovery and Development business leverages the company's platforms to identify and validate novel therapeutic targets, focusing on targeted therapy with drug conjugates, immune oncology, and cell therapy approaches.

Champions Oncology maintains approximately 1,500 patient-derived xenograft models in its proprietary TumorBank, characterized at molecular, phenotypic, and pharmacological levels. The company's Datacenter combines proprietary datasets with publicly available data, including approximately 3,500 molecular datasets, 3,000 clinical drug responses, and 3,500 in vivo drug responses alongside 20,000 publicly available datasets. The company has performed studies for approximately 500 different pharmaceutical and biotechnology companies across North America, Europe, and Asia.

As of July 2026, Champions Oncology employed 214 full-time employees, including 103 with doctoral or advanced degrees. The workforce comprises 149 employees in research and development and laboratory operations, 45 in sales and marketing, and 20 in finance, information technology, and administration. The company operates laboratory facilities in Rockville, Maryland. For fiscal year 2026, total revenues reached approximately $59.4 million.